Open AccessEpidemiology of invasive meningococcal disease in Canada, 2012–2019
Author(s) -
Myriam Saboui,
Raymond S. W. Tsang,
Robert MacTavish,
Amisha Agarwal,
Anita Li,
M Salvadori,
Susan Squires
Publication year - 2022
Publication title -
canada communicable disease report
Language(s) - English
Resource type - Journals
eISSN - 1481-8531
pISSN - 1188-4169
DOI - 10.14745/ccdr.v48i05a06
Subject(s) - incidence (geometry) , epidemiology , medicine , outbreak , population , vaccination , meningococcal disease , meningococcal vaccine , neisseria meningitidis , conjugate vaccine , pediatrics , demography , virology , immunology , biology , immunization , environmental health , antibody , bacteria , genetics , physics , sociology , optics
A variety of routine childhood and adolescent meningococcal vaccination programs using monovalent (serogroup C) and quadrivalent (A, C, Y, W) conjugate vaccines have been implemented in Canada since 2002, resulting in a decrease in invasive meningococcal disease (IMD) incidence, particularly in serogroup C. Meningococcal vaccines have also been used for outbreak response, including the multicomponent vaccine serogroup B vaccine. This report describes the epidemiology of IMD in Canada from 2012 to 2019.